Cannabis Extract Significantly Reduces Chemotherapy-Induced Vomiting, Tilray-Backed Study Reveals
On Thursday, Tilray Medical, a division of medical marijuana giant Tilray Brands, Inc. (NASDAQ:TLRY), announced the final results of a new scientific study, “Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV).” Results showed that cannabis extract significantly reduces chemotherapy-induced vomiting.
“These findings are encouraging for cancer patients undergoing chemotherapy,” stated Denise Faltischek, chief strategy officer and head of international at Tilray Brands. “This study is a crucial step in improving patient care and quality of life. Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV.”
Read Also: Tilray, High Tide, Glass House: How Top Cannabis Companies Deal With Financial Pressures
Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter